Skip to main content

Table 1 Treatment regimens of study interventions [Source: [11]]

From: Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy

Treatment

Treatment regimens

GO + DA (intervention)

Induction, course 1:

GO = 3 mg/m2 per day (max = 5 mg), on days 1–3 (2-h IV infusion)

DNR = 60 mg/m2 per day, on days 1–3 (30-min IV infusion)

AraC = 200 mg/m2 per day, on days 1–7 (continuous IV infusion)

Induction, course 2:

DNR = 35 mg/m2 per day, on days 1–3 (30-min IV infusion)

AraC = 1,000 mg/m2 per 12 h, on days 1–3 (12-h IV infusion)

Consolidation, course 1a:

GO = 3 mg/m2 per day (maximum = 5 mg), on day 1 (2-h IV infusion)

DNR = 60 mg/m2 per day, on day 1 (30-min IV infusion)

AraC = 1,000 mg/m2 per 12 h, on days 1–4 (2-h IV infusion)

Consolidation, course 2a:

GO = 3 mg/m2 per day (maximum = 5 mg), on day 1 (2-h IV infusion)

DNR = 60 mg/m2 per day, on days 1 and 2 (30-min IV infusion)

AraC = 1,000 mg/m2 per 12 h, on days 1–4 (2-h IV infusion)

DA (comparator)

Induction, course 1:

DNR = 60 mg/m2 per day, on days 1–3 (30-min IV infusion)

AraC = 200 mg/m2 per day, on days 1–7 (continuous IV infusion)

Induction, course 2:

DNR = 35 mg/m2 per day, on days 1–3 (30-min IV infusion)

AraC = 1,000 mg/m2 per 12 h, on days 1–3 (2-h IV infusion)

Consolidation, course 1a:

DNR = 60 mg/m2 per day, on day 1 (30-min IV infusion)

AraC = 1,000 mg/m2 per 12 h, on days 1–4 (2-h IV infusion)

Consolidation, course 2a:

DNR = 60 mg/m2 per day, on day 1 and 2 (30-min IV infusion)

AraC = 1,000 mg/m2 per 12 h, on days 1–4 (2-h IV infusion)

  1. AraC = cytarabine, CR = complete remission, CRp = complete remission with incomplete platelet recovery, DA = daunorubicin and cytarabine, DNR = daunorubicin, GO = gemtuzumab ozogamicin, IV = intravenous
  2. aGiven only to those patients who attained CR or CRp following induction therapy